Fig. 4
From: Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
Consensus recommendations for SSc-ILD treatment paradigm. A Treatment dosage and next steps following treatment response. B Use of nintedanib and tocilizumab. *Data from the 2022 supplementary Delphi. †Consensus was not reached in main Delphi analysis. CYC cyclophosphamide, HRCT high-resolution computed tomography, ILD interstitial lung disease, MMF mycophenolate mofetil, PFT pulmonary function test, SD standard deviation, SSc systemic sclerosis, TCZ tocilizumab